Why the study?
Are changes in NT-proBNP levels associated with the risk of CV death or HF hospitalization in patients with heart failure with preserved ejection fraction?
Are changes in NT-proBNP levels associated with the risk of CV death or HF hospitalization in patients with heart failure with preserved ejection fraction?
Monitoring changes in NT-proBNP levels may be a useful prognostic marker in patients with heart failure with preserved ejection fraction.
Answers are grounded in this paper and cite their sources.
NT-proBNP changes may refine HFpEF risk stratification; leaves open whether serial monitoring improves outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Jhund et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: